UNASSIGNED: A total of 100 subjects, comprising 50 patients with histopathologically confirmed OSCC and 50 age- and sex-matched healthy controls, were enrolled in the study. Salivary samples were collected from all participants and analyzed using enzyme-linked immunosorbent assays (ELISA) to measure IL-1 levels. Clinical data, including demographic information, smoking habits, and alcohol consumption, were obtained from patient records.
UNASSIGNED: The mean salivary IL-1 level was significantly higher in OSCC patients compared to healthy controls (P < 0.001). Furthermore, subgroup analysis demonstrated that advanced stages of OSCC correlated with significantly elevated IL-1 levels when compared to early-stage OSCC (P < 0.05). Additionally, high salivary IL-1 levels were associated with a more aggressive tumor phenotype and poorer prognosis, as reflected by tumor size, lymph node metastasis, and overall survival (P < 0.01).
UNASSIGNED: This case-control study provides compelling evidence that salivary Interleukin-1 (IL-1) levels are significantly elevated in patients with OSCC.
■总共100个科目,包括50例经组织病理学证实的OSCC患者和50例年龄和性别匹配的健康对照,参加了这项研究。从所有参与者收集唾液样品,并使用酶联免疫吸附测定(ELISA)进行分析以测量IL-1水平。临床数据,包括人口统计信息,吸烟习惯,和酒精消费,是从患者记录中获得的。
■OSCC患者的平均唾液IL-1水平明显高于健康对照组(P<0.001)。此外,亚组分析显示,与早期OSCC相比,晚期OSCC与IL-1水平显著升高相关(P<0.05).此外,高唾液IL-1水平与更具侵袭性的肿瘤表型和较差的预后相关,正如肿瘤大小所反映的,淋巴结转移,总生存期(P<0.01)。
这项病例对照研究提供了令人信服的证据,证明OSCC患者的唾液白细胞介素-1(IL-1)水平显着升高。